Over the Long Term, Antipsychotic Medicine Stabilized Functional Connectivity in Depressed Patients with Psychosis
Psychosis, which involves hallucinations, delusions, and other distortions of thought and perception, is often associated with schizophrenia. But it also occurs in other disorders, including major… Read More
New, Potential First-in-Class Schizophrenia Medicine Reduced Positive and Negative Symptoms in Phase 3 Trial
A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often… Read More
A Connectivity Signature Predicting Response to Antipsychotic Therapy is Identified in First-Episode Psychosis Patients
In people who experience a first psychotic episode—often the prelude to schizophrenia and related disorders—the individual’s response to antipsychotic medicines can be crucial, and typically, varies… Read More
In Schizophrenia, Reducing the Impact of Medications on One Neurotransmitter System Could Yield Gains in Cognition
Several important insights have recently combined to provide “a new lens” on improving how people with schizophrenia are cared for. This new perspective is arguably important not only for all… Read More
Stressful Life Events Can Cause Psychosis Relapse, Study Finds
There is considerable evidence that exposure to stressful life events can increase the risk that a vulnerable individual will go on to have a first psychotic episode. It has also been established… Read More